Evidence map›Paper›PMID 37302022›Full record

ArticleCancer biomarkers : section A of Disease markers2023

Cell-free circulating ALU repeats in serum have a prognostic value for colorectal cancer patients.

Isabel Anzinger, Dorothea Nagel, Enrico N De Toni, Andrea Ofner, Alexander B Philipp, Lesca M Holdt, Daniel Teupser, Frank T Kolligs, Andreas Herbst

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Isabel AnzingerDepartment of Urology, St. Elisabeth Hospital, Straubing, Germany.
Dorothea NagelInstitute of Laboratory Medicine, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
Enrico N De ToniMedical Department 2, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
Andrea OfnerMedical Department 2, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
Alexander B PhilippMedical Department 2, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
Lesca M HoldtInstitute of Laboratory Medicine, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
Daniel TeupserInstitute of Laboratory Medicine, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.
Frank T KolligsHelios Klinikum Berlin-Buch, Berlin, Germany.
Andreas HerbstMedical Department 2, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarcinoembryonic antigen (CEA) is the only established serum biomarker for colorectal cancer (CRC). To facilitate therapy decisions and improve the overall survival of CRC patients, prognostic biomarkers are required.

objectiveWe studied the prognostic value of five different cell free circulating DNA (fcDNA) fragments. The potential markers were ALU115, ALU247, LINE1-79, LINE1-300 and ND1-mt.

methodsThe copy numbers of the DNA fragments were measured in the peripheral blood serum of 268 CRC patients using qPCR, the results were compared to common and previously described markers.

resultsWe found that ALU115 and ALU247 fcDNA levels correlate significantly with several clinicopathological parameters. An increased amount of ALU115 and ALU247 fcDNA fragments coincides with methylation of HPP1 (P< 0.001; P< 0.01), which proved to be a prognostic marker itself in former studies and also with increased CEA level (both P< 0.001). ALU115 and ALU247 can define patients with poor survival in UICC stage IV (ALU115: HR = 2.9; 95% Cl 1.8-4.8, P< 0.001; ALU247: HR = 2.2; 95% Cl 1.3-3.6; P= 0.001). Combining ALU115 and HPP1, the prognostic value in UICC stage IV is highly significant (P< 0.001).

conclusionsThis study shows that an increased level of ALU fcDNA is an independent prognostic biomarker for advanced colorectal cancer disease.

Indexed as

Cell-Free Nucleic AcidsColorectal NeoplasmsBiomarkers, TumorCarcinoembryonic AntigenHumansPrognosisSerumBiomarkers, TumorCarcinoembryonic AntigenCell-Free Nucleic AcidsALU repeatsbiomarkersColorectal cancerfcDNAprognosis

Identifiers

PMID37302022
PMCPMC12412829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.